N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

N-Benzyladriamycin-14-valerate (AD198) is a novel lipophilic anthracycline with greater in vivo antitumour activity than doxorubicin (DOX) in experimental model systems. Using sensitive and progressively DOX-resistant L1210 mouse leukaemia and B16-BL6 mouse melanoma lines, we have determined the cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganapathi, R., Grabowski, D., Sweatman, T. W., Seshadri, R., Israel, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247277/
https://www.ncbi.nlm.nih.gov/pubmed/2605093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247277/
https://www.ncbi.nlm.nih.gov/pubmed/2605093

Ejemplares similares